Results from a Phase 3 clinical trial, CASPIAN, evaluating AstraZeneca’s (NYSE:AZN) Imfinzi (durvalumab), combined with platinum-based chemo compared to chemo alone or combined with tremelimumab and chemo versus chemo alone, for the treatment of small cell lung cancer in a first-line setting showed a statistically significant improvement in overall survival (OS).
Detailed data will be submitted for presentation at a future medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.